Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14

Loading news article.

Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14 | WAPE

Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14

Article summary

Related companies

Comments —